Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Statement | 16 July 2014 HIV/AIDS MSF response to UNAIDS' Gap report on the state of the HIV epidemic
Statement | 15 July 2014 Tuberculosis MSF calls on BRICS countries to prioritize health and access to medical innovation 5 min
Press release | 07 July 2014 Intellectual property and trade Canada Trans-Pacific trade partners must stand against higher medicine prices and take harmful provisions off the negotiating table
Photograph by Matthew Smeal Feature story Feature story | 03 July 2014 Tuberculosis Cambodia Managing Tuberculosis in Cambodia 4 min
Photograph by Rowan Pybus Press release Press release | 01 July 2014 Tuberculosis South Africa More MSF patients with DR-TB gain access to dramatically cheaper version of life-saving drug
Letter Letter | 18 June 2014 Hepatitis C Vaccines Civil society groups call on GAVI to support birth dose vaccination for hepatitis B
Photograph by Jose Cendon Press release Press release | 11 June 2014 Tuberculosis South Africa End DR-TB patients’ deadly waiting game now, MSF tells SA health authorities 5 min